Vicapsys Life Sciences (OTCMKTS:VICP) and InflaRx (NASDAQ:IFRX) Head-To-Head Review

Vicapsys Life Sciences (OTCMKTS:VICP) and InflaRx (NASDAQ:IFRX) are both small-cap construction companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Earnings and Valuation

This table compares Vicapsys Life Sciences and InflaRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicapsys Life Sciences	N/A	N/A	-$1.18 million	($0.03)	-50.33
InflaRx	$70,000.00	1,303.77	-$46.18 million	($0.89)	-1.74

Vicapsys Life Sciences has higher earnings, but lower revenue than InflaRx. Vicapsys Life Sciences is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vicapsys Life Sciences has a beta of -4.33, suggesting that its stock price is 533% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.

Profitability

This table compares Vicapsys Life Sciences and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicapsys Life Sciences	N/A	N/A	N/A
InflaRx	-44,046.09%	-47.03%	-41.56%

Institutional and Insider Ownership

42.4% of InflaRx shares are owned by institutional investors. 6.0% of Vicapsys Life Sciences shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vicapsys Life Sciences and InflaRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicapsys Life Sciences	0	0	0	0	N/A
InflaRx	0	0	1	1	3.50

InflaRx has a consensus target price of $13.50, indicating a potential upside of 770.97%. Given InflaRx’s higher probable upside, analysts clearly believe InflaRx is more favorable than Vicapsys Life Sciences.

Summary

InflaRx beats Vicapsys Life Sciences on 8 of the 13 factors compared between the two stocks.

About Vicapsys Life Sciences

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.